650 PATENT ABSTRACTS

was Constructed with fragments of the gene. Recombinant DNA clones producing specific antigenic determinants were isolated using monoclonal antibodies and the sequences of their insert DNAs were determined with a rapid primer extension method. Amino acid sequences for six different epitopes of the M. leprae protein were elucidated. A peptide containing sequences for one of these epitopes, which is unique to M. leprae, was synthesized and shown to bind the appropriate monoclonal antibody; The ap- proach described here can be used to elucidate rapidly protein epitopes that are recognized by antibodies or T cells. In addition, the well- characterized M. leprae antigens can be used in prevention, diagnosis and treatment of leprosy.

4908203

M E T H O D F O R I N D U C I N G H I V N E U T R A L I Z I N G A N T I B O D I E S U S I N G A N I N T E R N A L I M A G E

I D I O T O P E

George Thornton, Rancho Bernardo, Canada assigned to Johnson & Johnson

The present invention contemplates a method for inducing a HIV neutralizing immune response using an OKT4A antibody molecule homolog as an immunogen. Vaccines for prac- ticing an immunization method of this invention are also described.

4908204

R E V E R S I B L Y B L O C K E D P L A S M I N , T - P A H Y B R I D

F I B R I N O L Y T I C E N Z Y M E S A N D P H A R M A C E U T I C A L

C O M P O S I T I O N S A N D A N T I - T H R O M B O T I C U S E T H E R E O F

Jeffery H Robinson, Ian Dodd, Epsom, United Kingdom assigned to Beecham Group p I c

A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group.

4908305

C O M P E T I T I V E E L I S A F O R D E T E R M I N A T I O N O F

N E U T R A L I Z I N G I B D V A N T I B O D Y

David B Snyder assigned to The University of Maryland

A method for determining the level of infectious bursal disease virus IBDV neutralizing antibody in poultry comprising a labeled monoclonal anti- body R63 having the IBDV neutralizing cap- ability of the monoclonal antibody expressed by hybridoma cell line ATCC HB-9490. Mono- clonal antibody R63 is specific to all known IBDV strains and serotypes and competes only with itself and other antibodies recognizing the same neutralizing epitope present in poultry sera. In a competition assay, the increase in un- bound labeled monoclonal antibody is an indication of the level of IBDV neutralizing anti- body present in poultry sera.

4908306

H U M A N P A P I L L O M A V I R U S 56 N U C L E I C A C I D H Y B R I D I Z A T I O N

P R O B E S A N D M E T H O D S F O R E M P L O Y I N G T H E S A M E

Attila T Lorincz assigned to Life Technologies lnc

Nucleic acid hybridization probes for human papillomavirns types and particularly human papillomavirns type 56; and methods for em- ploying the same.

4908308

M E T H O D F O R D E T E C T I N G A N I M A L - I N F E C T I V E P R O T O Z O A IN V I T R O A N D A M E T H O D F O R

D E T E C T I N G A G E N T S W H I C H B L O C K T H E D I F F E R E N T I A T I O N

T H E R E O F

Ploeg Lex H T Van der, Suzanne H Giannini, Charles Cantor assigned to The Trustees of Columbia University in the City of New York

This invention concerns a method for iden- tifying in vitro an animal-infective form of a parasitic protozoan which comprises recovering total mRNA from the protozoan and detecting

PATENT

in the mRNA so recovered the presence of a mRNA transcript encoding a heat shock protein associated with animal-infective parasitic pro- tozoans, which transcript is present only in the animal-infective form of the protozoan, or quan- titatively determining in the mRNA so recovered the number of a mRNA transcript encoding a heat shock protein associated with animal- infective parasitic protozoans, which transcript is present in increased number only in the animal-infective form of the parasitic protozoan. This invention also concerns a method for iden- tifying an agent capable of blocking the forma- tion of the animal-infective form of a parasitic protozoan.

ABSTRACTS

4908432

N O V E L P O L Y P E P T I D E H A V I N G G A M M A - I N T E R F E R O N A C T I V I T Y

Yum K Yip assigned to New York University

The present invention provides a peptide having an amino acid sequence of less than about 100 amino acids, immunochemically reactive with an antibody directed against human gamma- interferon, and displaying gamma-interferon antiviral and cytolytic activities.

4908316

S T R E P T O M Y C E S S P . N664-30 W H I C H P R O D U C E S A N

I O N O P H O R E A N T I B A C T E R I A L A G E N T

Walter P Cullen, John R Oscarson, Junsuk Tone, Hiroshi Maeda assigned to Pfizer Inc

An antibiotic has been isolated from fermenta- tion of a new Streptomyces culture. The new ionophore is active as an antibacterial and anti- coccidial agent.

4908431

M O N O C L O N A L A N T I B O D I E S T O H U M A N K I N I N O G E N A N D

M E T H O D S O F P R E P A R I N G S A M E

Robert W Colman, Alvin H Schmaier assigned to Temple University-of the Commonwealth System of Higher Education

Two novel cell lines, ATCC £HB-8963 and ATCC £HB-8964 produce monoclonal antibody to human kininogen. One of the antibodies specifically recognizes the heavy chain of high and low molecular weight kininogen (the later protein is identical to alpha cysteine protease in- hibitor). The other antibody recognizes the light chain of high molecular weight kininogen. The hybridomas are formed by fusing spleen cells from immunized BALB/c AnSkh mice with P3X63Ag8 or SP2/0-Agl4 myeloma cells. Dia- gnostic, therapeutic and biochemical uses of the monoclonal antibodies are provided.

651

4908433

U S E S O F I N T E R L E U K I N - 2

Roland Mertelsmann, Kar Welte, Salvatore Venuta assigned to Sloan-Kettering Institute for Cancer Research

Interleukin 2 (IL 2; T-cell growth factor), pro- duced with and without costimulation by Bur- kitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal human blood cells by (NH4)2SO4-precipitation, ion exchange chromatography, gel filtration and hydrophobic chromatography, hp IL-2 is free of pyrogens, B cell inducing factor, B cell growth factor, inter- feron, CSF, and thymocyte differentiating fac- tor. Nature IL 2 produced in the absence of Daudi cells has a molecular weight of about 26,000 daltons as measured by gel filtration and yields II 2 having two molecular weights of about 16,000 and 17,000 daltons after denaturation as measured by sodium dodecyl sulfate- poylacrylamide gel electrophoresis, IL 2 pro- duced in the presence of Daudi cells shows a molecular weight of approximately 14,500 dal- tons as measured by both gel filtration and sodium dodecyl sulfate-polyacrylamide gel elec- trophoresis.

49O8434

PROCESS FOR PREPARING PURIFIED INTERLEUKIN-2

Roland Mertelsmann, Kar Welte, Salvatore Venuta assigned to Sloan-Kettering institute for Cancer Research

Interleukin 2 (IL 2; T-eell growth factor), pro- duced with and without costimulation by Bur-